News | Radiation Therapy | August 26, 2019

Moffitt Researchers Develop Model to Personalize Breast Cancer Radiation Treatment

The genomically-adjusted radiation dose (GARD) can predict risk of local tumor recurrence and optimize radiation dose

Moffitt Researchers Develop Model to Personalize Breast Cancer Radiation Treatment

August 26, 2019 — A personalized approach to cancer treatment has become more common over the last several decades, with numerous targeted drugs approved to treat particular tumor types with specific mutations or patterns. However, this same personalized strategy has not translated to radiation therapy, and a one-size-fits-all approach for most patients is still common practice. Moffitt Cancer Center researchers hope to change this mindset for radiation treatment with the development of a genomically-based model that can optimize and personalize a radiation dose to match an individual patient’s needs.

Radiation therapy is part of the standard treatment approach for breast cancer, but the dose administered to most patients is largely the same. Currently, clinical studies are being conducted to determine the benefits and risks of omitting radiation treatment in certain patients with breast cancer who are at a low risk of local disease recurrence. However, according to Javier Torres-Roca, M.D., senior member of Moffitt’s Department of Radiation Oncology, “a true genomic approach to personalize radiotherapy dose has not yet been undertaken.”

Previously, Torres-Roca and his team developed and validated a radiation sensitivity index (RSI) to predict the radiation sensitivity of tumors based on the patterns of 10 genes. However, they wanted to further develop the use of the RSI to more accurately determine the appropriate radiation dose for individual patients. The research team combined the RSI with a model that is used to determine the effect of radiation dose on tumor and normal tissues to create a new radiation dose determining method called genomically-adjusted radiation dose (GARD).

“GARD is the first opportunity for a genomically-driven personalized approach in radiation oncology, and is a research priority for the field,” explained Torres-Roca. “Our research has found that GARD values are lower for those tumors that are resistant to radiation and higher for those tumors that are sensitive to radiation treatment.”

In a new study published this month in EBioMedicine, Moffitt researchers validated the use of the GARD model in two separate groups of triple-negative breast cancer patients treated with radiation therapy from Europe (N=58) and the Total Cancer Care program at Moffitt (N=55).1 They demonstrated that GARD values were associated with the risk of breast cancer recurring locally. The researchers also used GARD to calculate an individualized radiation dose for each breast cancer patient in the group of patients from Moffitt. They found that the range for biological optimal radiation dose in triple negative breast cancer ranged from 30 to 76 Gy, and that the current standard to deliver 60 Gy to all patients could be overdosing a significant number of patients.

The researchers are now planning a clinical trial to be initiated at Moffitt where the radiation dose for breast cancer patients will be selected based on this model. They hope that the continued study of the GARD model and its implementation into practice will benefit patients by allowing a personalized approach to radiation treatment and will minimize the risks of additional radiation exposure. 

“Our analyses provide the first proposed range for optimal radiotherapy dose at an individual patient level in triple-negative breast cancer and proposes a significant number of patients can be treated with lower doses of radiotherapy while still maintaining high levels of local control,” said Kamran Ahmed, M.D., assistant member of the Department of Radiation Oncology at Moffitt and lead author of the study.

The study was supported by funds from the Morton Plant Mease Foundation.

For more information: www.ebiomedicine.com

 

Related Content

VIDEO: Personalizing Radiotherapy Using Genomic Markers of Radiosensitivity

Researchers Develop First Genetic Test Predicting Tumor Sensitivity to Radiotherapy

Radiation Therapy Treatment Advances

 

Reference

1. Ahmed K.A., Liveringhouse C.L., Mills M.N., et al. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management. EBioMedicine, published online Aug. 12, 2019. https://doi.org/10.1016/j.ebiom.2019.08.019

Related Content

After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center

Image by Rudolf Langer from Pixabay 

News | Clinical Trials | December 06, 2019
December 6, 2019 — After receiving acupuncture treatment three days a week during the course of...
Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University

Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University. Photo courtesy of McMaster University

News | Breast Imaging | December 06, 2019
December 6, 2019 — A shorter course of higher-dose radiation treatment to part of the breast is showing promise in wo
Sponsored Content | Videos | Quality Assurance (QA) | December 06, 2019
Modus QA is proud to offer a superior phantom for quantifying geometric distortion in modern MRgRT applications. Watc
MRI Exablate neuro helmet from INSIGHTEC

MRI Exablate neuro helmet from INSIGHTEC. Image courtesy of Ali Rezai, M.D., and RSNA.

News | Clinical Trials | December 03, 2019
December 3, 2019 — Focused ultrasound is a safe and effective way to target and open areas of the blood-brain barrier
Image by Kira Hoffmann from Pixabay  #RSNA19

Image by Kira Hoffmann from Pixabay 

News | Clinical Trials | November 30, 2019
November 30, 2019 — Researchers are trying to identify injury patterns and predict future outcomes for victims of gun
#RSNA19 GE Healthcare introduced Serena Bright, the healthcare industry’s first contrast-enhanced mammography solution for biopsy
News | Mammography | November 30, 2019
November 30, 2019 — To help empower clinicians and patients in their fight against...
This bar graph shows breast cancer presentation by screening interval #RSNA19

This bar graph shows breast cancer presentation by screening interval. Image courtesy of study author and RSNA

News | Breast Imaging | November 28, 2019
November 28, 2019 — Cancers found in patients undergoing annual...